The Current FDA Landscape
The FDA regulates breast implants as Class III medical devices, requiring premarket approval (PMA) and post-approval studies. Both Allergan (AbbVie) and Mentor (Johnson & Johnson) run ongoing post-approval studies tracking long-term safety outcomes for their approved silicone and saline implants. Establishment Labs (Motiva implants) received FDA approval in 2024, bringing a third major silicone gel implant to the US market with novel surface technology.
Adjustable Implants
Several adjustable implant systems allow volume modification after surgery through a subcutaneous port. AeroForm tissue expanders (AirXpanders) use compressed CO2 rather than saline injection, allowing patient-controlled expansion at home without clinic visits. Research continues on fully adjustable permanent implants where volume can be fine-tuned in the months following surgery before the port is removed.
Bioabsorbable Internal Scaffolds
GalaFLEX and similar bioabsorbable mesh scaffolds are used alongside implants to provide structural support during healing, gradually absorbing as the patient's own tissue remodels around them. Research is ongoing into whether such scaffolds can meaningfully extend aesthetic longevity and reduce revision rates for high-volume implants where ptosis is the primary long-term concern.
Stem Cell-Enhanced Fat Transfer
Stromal vascular fraction (SVF) enrichment of fat grafts with concentrated stem cells is being investigated as a method to improve fat survival rates above the current 40–80% range. Early clinical data suggests SVF-enriched grafts may survive at higher rates, potentially making fat transfer viable for larger volume augmentations. FDA oversight of SVF procedures has been evolving.
Next-Generation Silicone Gels
Research into more highly cohesive gel formulations continues — gels that maintain shape better under load while retaining natural feel. The Mentor MemoryGel Enhance range, FDA-approved in 2024, specifically targets larger-volume patients with improved projection stability at high fill volumes. This addresses a documented clinical challenge with large implants: progressive implant deformation under sustained gravity load.
Tissue-Engineered Scaffolds
Long-term research programmes are investigating fully biological breast reconstruction using decellularised extracellular matrix scaffolds seeded with the patient's own cells. This approach — if successful — could eventually provide augmentation using entirely biological material without permanent foreign body implantation. Human trials remain years away for this application.
